AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2012
Dec 26, 2012
32418_dirs_2012-12-26_cea8f8ab-894d-454f-a4fb-145710be8758.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-12-21
Reporting Person: HALPRYN GLENN L (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-12-21 | Employee Stock Options (right to buy) | $1.545 | D | 82500 | Disposed | 2020-05-20 | Common Stock (82500) | Direct |
| 2012-12-21 | Employee Stock Options (right to buy) | $1.54 | D | 82500 | Disposed | 2021-05-10 | Common Stock (82500) | Direct |
| 2012-12-21 | Employee Stock Options (right to buy) | $0.945 | A | 106809 | Acquired | 2022-09-15 | Common Stock (106809) | Direct |
Footnotes
F1: These previously awarded options have been terminated in exchange of a new award of options under different terms.
F2: Options vested 1/12th every month for 12 months and have been fully vested as of May 20, 2011.
F3: Options vested 1/12th every month for 12 months and have been fully vested as of May 10, 2012.
F4: These new options are awarded by terminating the previously awarded options under different terms.
F5: Options vest 1/12th every month for 12 months and will be fully vested on September 15, 2013.
F6: The total includes 82,500 options under different terms.